Test Center

My Recent Searches

  • No Recent Search.

My Tests Viewed

  • No Test Viewed.

JAK2 and MPL Mutation Analysis

JAK2 and MPL Mutation Analysis

Test Summary

JAK2 and MPL Mutation Analysis

  

Clinical Use

  • Diagnose polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (MF)

  • Monitor patients for therapeutic response and relapse (quantitative JAK2 V617F mutation analysis only)

Clinical Background

Chronic myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell malignancies characterized by excessive production of blood cells. ET, MF, and PV are the 3 most common BCR/ABL1-negative MPNs and are associated with thrombosis and hemorrhage, splenomegaly, and the risk of transformation to acute myeloid leukemia.

Diagnostic criteria for ET, MF, and PV adopted by the World Health Organization (WHO) include identification of a clonal marker, with a specific recommendation to test for the JAK2 V617F mutation in exon 14.1 JAK2 V617F is a gain-of-function mutation that leads to clonal proliferation; it is present in about 95% of PV cases and about half of ET and MF cases. The JAK2 allele burden decreases with successful therapy, disappears in some patients, and reappears during relapse.2,3 Thus, quantitative JAK2 analysis may be useful for diagnosis and patient management. In JAK2 V617F-negative patients, the presence of a JAK2 exon 12 mutation also meets the WHO criterion for establishing clonality. Exon 12 mutations have been found in patients with PV who present with erythrocytosis but are typically not associated with ET or MF (Table 1).4,5

Table 1. Prevalence of Somatic Mutations in PV, ET, and MF4-6
 

JAK2 V617F

Mutation,%

JAK2 Exon 12

Mutation,%

MPL W515

Mutation,%
Polycythemia vera (PV) 95 2–4 0
Essential thrombocythemia (ET) 50 0 1
Myelofibrosis (MF) 50 0a 5–7

a Only limited data are available.

Because a significant proportion of patients with ET or MF are negative for JAK2 mutations, other somatic mutations were sought; hence mutations in the myeloproliferative leukemia gene (MPL) were identified.8 MPL, found at chromosome 1p34, encodes the thrombopoietin receptor that works in concert with thrombopoietin for platelet production. Acquired MPL mutations (eg, W515L and W515K) are associated with severe anemia and have been detected in patients with ET or MF but not in patients with PV (Table 1).6,7 An inherited MPL mutation (S505N; exon 10) has also been found in a Japanese pedigree with familial ET.8

Although mutation analysis testing frequently uses bone marrow or peripheral blood cells, the Leumeta® tests employed by Quest Diagnostics are performed using plasma samples. For JAK2 mutation testing, plasma was shown to provide a higher mutation detection rate,9 to distinguish hemizygous/homozygous from heterozygous mutations,10 and to detect mutations in RNA that might be missed with DNA cell-based testing.11

For diagnostic purposes, test selection is best based on the hematologic characteristics and relative prevalence of JAK2 and MPL mutations in patients with BCR/ABL1-negative MPNs. Typically, mutations in MPL and JAK2 exon 12 are investigated after the JAK2 V617F mutation has been ruled out (Figure).

Figure. JAK2 and MPL mutation analysis (test code 16538X) testing cascade.

Individuals Suitable for Testing

  • Individuals suspected of having PV, ET, or MF

  • JAK2 V617F mutation-positive individuals undergoing treatment for PV, ET, or MF

Available Tests (Table 2)
Table 2. JAK2 and MPL Mutation Assays
Test Code Test Name
16175 JAK2 Mutation (V617F) Analysis, Quantitative, Plasma-based, Leumeta
16536X JAK2 Exons 12 and 13 Mutations, Qualitative, Leumetaa
16539X JAK2 V617F Mutation, Qualitative PCR, Leumeta with Reflex to Exons 12, 13a
16538X JAK2 V617F, QL, Leumeta with Reflex to Exons 12, 13 and Reflex to MPL W515 and MPL S505a
16184X MPL W515 and MPL S505 Mutation Analysis, Qualitative, Leumeta

a  Reflex tests are performed at an additional charge and are associated with an additional CPT code(s). Reflex testing is performed when initial mutation results are negative.

Method

  • Reverse transcription-PCR amplification targeting relevant regions of JAK2 or MPL, followed by amplicon sequencing and computer analysis for the presence of mutations

  • Analytical sensitivity (qualitative tests): 10% mutant allele in the background of wild-type allele

  • Analytical sensitivity (quantitative test): 5 pg JAK2 V617F/μL plasma

  • Results reported vary with the test:

–   JAK2 V617F qualitative tests: positive (homozygous, homozygous/hemizygous, heterozygous) or

negative

–   JAK2 V617F quantitative test: pg JAK2 V617F/μL plasma

–   JAK2 exon 12 and 13 mutations: positive or negative

–    MPL W515 and S505 mutations: positive or negative for each mutation; any additional mutations

 detected

Reference Range

Negative for mutation

Interpretive Information

The presence of a JAK2 V617F or exon 12 mutation is consistent with the diagnosis of PV. JAK2 V617F-positive results may also be associated with ET, MF, or, rarely, with other myeloid neoplasms.1 In patients with suspected ET or MF, a JAK2 V617F-positive result rules out reactive thrombocytosis and myelofibrosis.1 A negative result does not rule out the diagnosis of PV, ET, or MF. When monitoring disease, a decrease in JAK2 V617F concentration suggests therapeutic response; an increase suggests relapse.

The presence of a MPL W515 mutation is consistent with ET or MF and meets the WHO diagnostic criterion for establishing clonality; MPL S505N is consistent with familial ET. A negative finding does not rule out ET or MF.

These assays detect mutations only in the exons tested; polymorphisms or mutations at other locations will not be detected. Test results should be interpreted in conjunction with other laboratory and clinical findings. False-negative results may occur when there is a low mutant allele burden in the peripheral blood.

References

  1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14-22.

  2. Kiladjian JJ, Cassinat B, Turlure P, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a. Blood. 2006;108:2037-2040.

  3. Kröger N, Badbaran A, Holler E, et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood. 2007;109:1316-1321.

  4. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459-468.

  5. Pardanani A, Lasho TL, Finke C, et al. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia. 2007;21:1960-1963.

  6. Pancrazzi A, Guglielmelli P, Ponziani V, et al. A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. J Mol Diagn. 2008;10:435-441.

  7. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:1140-1151.

  8. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103:4198-4200.

  9. Ma W, Kantarjian H, Zhang X, et al. Higher detection rate of JAK2 mutation using plasma. Blood. 2008;111:3906-3907.

  10. Ma W, Kantarjian H, Verstovsek S, et al. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behavior. Br J Haematol. 2006;134:341-350.

  11. Ma W, Kantarjian H, Zhang X, et al. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn. 2009;11:49-53.
     

These tests were developed and performance characteristics have been determined by Quest Diagnostics Nichols Institute. Performance characteristics refer to the analytical performance of the test.
Content reviewed 12/2012
 
top of page

* The tests listed by specialist are a select group of tests offered. For a complete list of Quest Diagnostics tests, please refer to our Directory of Services.